All In Biotech

Drug Trial Radar · NCT06435273

Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Aug 5, 2024

Primary completion

Oct 15, 2025

Study completion Oct 15, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: * The study duration for each participant will be approximately 10 weeks. * The duration of IMP administration will be approximately 4 weeks.

Conditions

  • Asthma

Interventions

  • AZD4604Drug

    Janus kinase 1 (JAK1) inhibitor

  • Placebo to AZD4604Drug

    Placebo to AZD4604

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to end of investigational medicinal product (IMP) administration in expression of T2 and non-T2, and JAK1-related genes and gene signatures in bronchial brushingsTime frame: 4 weeks

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    København NV, Denmark

  • Research Site

    Frankfurt, Germany

  • Research Site

    Großhansdorf, Germany

  • Research Site

    Barcelona, Spain

  • Research Site

    Palma de Mallorca, Spain

  • Research Site

    Santander, Spain

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    Glasgow, United Kingdom

  • Research Site

    Headington, United Kingdom

  • Research Site

    Leicester, United Kingdom

  • Research Site

    Liverpool, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.